Ultrasound-driven piezoelectric nanomaterial platform enables wireless neuromodulation for Parkinson’s disease
Source abstract
Abstract
Parkinson's disease (PD) is characterized by progressive dysfunction of the basal ganglia circuitry, leading to both motor and cognitive impairments. Current neuromodulation strategies for deep brain targets remain highly invasive and lack precise spatiotemporal controllability. For example, traditional deep brain stimulation offers substantial relief from PD's movement-related symptoms by surgically placing electrodes in the subthalamic nucleus (STN), but this procedure carries substantial risks including intracranial hemorrhage and infection. Herein, we report an ultrasound-driven piezoelectric neuromodulation platform for minimally invasive regulation of STN-associated circuitry in PD. Barium titanate piezoelectric nanoparticles (BTNPs) with a typical non-centrosymmetric tetragonal phase were fabricated and stereotactically delivered into the STN. Upon ultrasound stimulation, BTNPs generated localized microelectric signals through piezoelectric conversion for wireless modulation of neuronal activity. Ultrasound-activated BTNPs modulated neuronal activity within the STN-associated basal ganglia circuitry and increased movement-evoked dopamine release in the striatum, suggesting improved nigrostriatal dopaminergic function. These effects were accompanied by increased tyrosine hydroxylase expression and reduced dopaminergic neuronal loss in the substantia nigra. Following a one-week treatment with targeted STN neuromodulation, PD mice showed significant enhancements in both motor and cognitive abilities. Collectively, this work establishes a controllable and minimally invasive piezoelectric strategy for deep-brain neuromodulation and provides mechanistic insight into STN-associated circuit regulation in PD. STATEMENT OF SIGNIFICANCE: Deep brain stimulation is effective for Parkinson's disease (PD) but requires surgically implanted electrodes and battery-powered pulse generators. Here, we present an ultrasound-driven piezoelectric nanomaterial platform that enables wireless neuromodulation of deep brain regions. Barium titanate piezoelectric nanoparticles were stereotactically delivered into the subthalamic nucleus, where ultrasound stimulation triggered localized electromechanical transduction, enabling neuronal modulation without implanted electrodes. In an MPTP-induced PD mouse model, this approach alleviated motor and cognitive deficits, restored pathological neural activity, and enhanced movement-evoked dopamine release. Furthermore, chemogenetic manipulation confirmed that subthalamic nucleus activity mediates these therapeutic effects. This study establishes a biomaterial-enabled strategy for wireless deep brain neuromodulation and advances non-electrode-based neuromodulation for PD.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Ultrasound and Hyperthermia Applications · Vagus Nerve Stimulation Research · Neurological disorders and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Parkinson’s disease10.1016/S0140-6736(14)61393-3 ↗
2. Diagnosis and treatment of Parkinson disease: a review10.1001/jama.2019.22360 ↗
3. The basal ganglia and adaptive motor control10.1126/science.8091209 ↗
4. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease10.1517/14656566.2015.1086747 ↗
5. Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration10.1038/ncomms12932 ↗
6. Clinical spectrum of levodopa-induced complications10.1002/mds.26125 ↗
7. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia10.1111/j.1471-4159.2009.06556.x ↗
8. MDS clinical diagnostic criteria for Parkinson’s disease10.1002/mds.26424 ↗
9. Therapeutic deep brain stimulation reduces cortical phase-amplitude coupling in Parkinson’s disease10.1038/nn.3997 ↗
10. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial10.1016/S1474-4422(12)70264-8 ↗
11. CSP 468 Study Group, bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial10.1001/jama.2008.929 ↗
12. Wireless deep brain stimulation by ultrasound-responsive molecular piezoelectric nanogenerators10.1021/acsnano.3c10227 ↗
13. Long-term outcomes of deep brain stimulation in Parkinson disease10.1038/s41582-019-0145-9 ↗
14. Recent advances of energy solutions for implantable bioelectronics10.1002/adhm.202100199 ↗
15. Deep brain stimulation: current challenges and future directions10.1038/s41582-018-0128-2 ↗
16. Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis10.1001/jamaneurol.2014.4380 ↗
17. Transcranial direct current stimulation for balance rehabilitation in neurological disorders: a systematic review and meta-analysis10.1016/j.arr.2022.101736 ↗
18. Piezotronic and piezo-phototronic effects on sonodynamic disease therapy10.1002/bmm2.12006 ↗
19. Neuromodulation of the peripheral nervous system: bioelectronic technology and prospective developments10.1002/bmm2.12048 ↗
20. Transcranial magnetic stimulation in basic and clinical neuroscience: a comprehensive review of fundamental principles and novel insights10.1016/j.neubiorev.2017.10.006 ↗
21. Magnetothermal nanoparticle technology alleviates parkinsonian-like symptoms in mice10.1038/s41467-021-25837-4 ↗
22. A nanoparticle-based wireless deep brain stimulation system that reverses Parkinson’s disease10.1126/sciadv.ado4927 ↗
23. Advanced near-infrared light approaches for neuroimaging and neuromodulation10.1002/bmm2.12023 ↗
24. Ultrasound active piezoelectric nanostimulators for long-acting wireless deep brain electric stimulation to inhibit epileptic seizures
25. Ultrasound-driven in vivo electrical stimulation based on biodegradable piezoelectric nanogenerators for enhancing and monitoring the nerve tissue repair10.1016/j.nanoen.2022.107707 ↗
26. Barium titanate nanoparticles: promising multitasking vectors in nanomedicine10.1088/0957-4484/27/23/232001 ↗
27. Deep brain stimulation by blood-brain-barrier-crossing piezoelectric nanoparticles generating current and nitric oxide under focused ultrasound10.1038/s41551-022-00965-4 ↗
28. Piezoelectric nanoparticle-assisted wireless neuronal stimulation10.1021/acsnano.5b03162 ↗
29. Piezoelectric ultrasound energy-harvesting device for deep brain stimulation and analgesia applications10.1126/sciadv.abk0159 ↗
30. Piezoelectric neuromodulation of the subthalamic nucleus ameliorates motor and nonmotor symptoms of Parkinson’s disease10.1126/sciadv.aec6955 ↗
31. Piezoelectric nanogenerators enabled neuromodulation rescued dopaminergic neuron loss in Parkinson’s disease10.1016/j.nanoen.2023.109187 ↗
32. Ultrasound active piezoelectric nanostimulators for long-acting wireless deep brain electric stimulation to inhibit epileptic seizures
33. Acute and separate modulation of motor and cognitive performance in parkinsonian rats by bilateral stimulation of the subthalamic nucleus10.1016/j.expneurol.2004.12.025 ↗
34. The role of the subthalamic nucleus in cognition10.1515/revneuro-2012-0075 ↗
35. Oxytocin protects nigrostriatal dopamine signal via activating GABAergic circuit in the MPTP-induced Parkinson’s Disease model10.4028/b-wjQRP6 ↗
36. Wearable ultrasound improves motor function in an MPTP mouse model of Parkinson’s Disease10.1109/TBME.2019.2899631 ↗
37. Piezoelectric nanoparticle-driven rhythmic ultrasound neuromodulation for treatment of early-stage Alzheimer’s disease10.1016/j.biomaterials.2025.123905 ↗
38. Piezocatalytic tumor therapy by ultrasound-triggered and BaTiO3 -mediated piezoelectricity10.1002/adma.202001976 ↗
39. The MPTP Story10.3233/JPD-179006 ↗
40. Near-infrared radiation-assisted drug delivery nanoplatform to realize blood-brain barrier crossing and protection for parkinsonian therapy10.1021/acsami.1c12675 ↗
41. Noninvasive ultrasound deep brain stimulation for the treatment of Parkinson’s Disease model mouse10.34133/2019/1748489 ↗
42. Protocol for the MPTP mouse model of Parkinson’s disease10.1038/nprot.2006.342 ↗
43. Ferroelectric state and polarization switching behaviour of ultrafine BaTiO3 nanoparticles with large-scale size uniformity10.1039/D0TC05975G ↗
44. Ferroelectric order in individual nanometre-scale crystals10.1038/nmat3371 ↗
45. Ultrasound-activated piezoelectric nanostickers for neural stem cell therapy of traumatic brain injury10.1038/s41563-025-02214-w ↗
46. BaTiO3-based piezoelectrics: fundamentals, current status, and perspectives10.1063/1.4990046 ↗
47. Life cycle assessment of lead-free potassium sodium niobate versus lead zirconate titanate: energy and environmental impacts10.1002/eom2.12450 ↗
48. Deep brain stimulation by blood-brain-barrier-crossing piezoelectric nanoparticles generating current and nitric oxide under focused ultrasound10.1038/s41551-022-00965-4 ↗
49. Mapping patterns of c-fos expression in the central nervous system after seizure10.1126/science.3037702 ↗
50. c-fos and related immediate early gene products as markers of activity in neuroendocrine systems10.1006/frne.1993.1006 ↗
51. Deep brain stimulation of hypothalamus for narcolepsy-cataplexy in mice10.1016/j.brs.2020.04.006 ↗
52. The origin of extracellular fields and currents–EEG, ECoG, LFP and spikes10.1038/nrn3241 ↗
53. New insights into the relationship between dopamine, beta oscillations and motor function10.1016/j.tins.2011.09.003 ↗
54. Subthalamic synchronized oscillatory activity correlates with motor impairment in patients with Parkinson’s disease10.1002/mds.26759 ↗
55. Theta frequency deep brain stimulation in the subthalamic nucleus improves working memory in Parkinson’s disease10.1093/brain/awad433 ↗
56. Relationship between oscillatory activity in the cortico-basal ganglia network and parkinsonism in MPTP-treated monkeys10.1016/j.nbd.2014.04.004 ↗
57. Cognitive effects of theta frequency bilateral subthalamic nucleus stimulation in Parkinson’s disease: a pilot study10.1016/j.brs.2020.12.014 ↗
58. Regulation of tyrosine hydroxylase gene expression during hypoxia: role of Ca2+ and PKC10.1038/ki.1997.74 ↗
59. Modifying the progression of Alzheimer’s and Parkinson’s disease with deep brain stimulation10.1016/j.neuropharm.2019.107860 ↗